Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Pfizer has agreed to pay Nona Biosciences up to $1.1 billion for an investigational mesothelin-targeted antibody-drug conjugate called HBM9033. The deal…
Pfizer has struck another Chinese-origin antibody-drug conjugate deal, agreeing to pay Nona Biosciences and Harbour BioMed up to $1.1 billion for global rights…
Pfizer to present Phase 1 clinical study design for MesoC2 (HBM9033/PF-08052666), an MSLN-targeting ADC, at ASCO 2025 (abstract TPS3163); Phase 1…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Pfizer entered an exclusive global license agreement with Nona Biosciences (a wholly owned subsidiary of Harbour BioMed) for HBM9033, an investigational MSLN-targeted antibody-drug conjugate for solid tumors, announced December 14, 2023. Nona received $53M upfront and near-term payments, up to $1.05B in development/commercial milestones, plus tiered royalties ranging from high single digits to high teens. Since the deal, Pfizer has advanced the asset (now also designated PF-08052666 / SGN-MesoC2, or "MesoC2") into the clinic: the Phase 1 open-label dose-escalation/expansion study NCT06466187 (sponsored by Seagen, a wholly owned Pfizer subsidiary) began August 2, 2024 in advanced solid tumors including mesothelioma, platinum-resistant ovarian cancer, pancreatic ductal adenocarcinoma, NSCLC, endometrial cancer and colorectal cancer, enrolling up to ~365 patients. Pfizer presented the Phase 1 study design at ASCO 2025 (poster TPS3163, June 2, 2025) and preclinical data on the TOP1i-based MSLN ADC at AACR 2025; the trial was active (not recruiting) as of mid-2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Nona Biosciences (Harbour BioMed subsidiary) (this deal) | 2023 | $1.1B | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2023 deals · Pfizer Inc. deals · Oncology deals